Robert Cesaro
Associate @ Arboretum Ventures
Robert Cesaro is a Series B investor at Arboretum Ventures focused on Health Care and Medical Device. Rob Cesaro joined Arboretum Ventures in 2008 as an Analyst. His efforts are focused primarily on reviewing new investment opportunities and providing operational support to Arboretum's portfolio companies. Rob has been involved with many of Arboretum’s most recent investments, including completing much of the due diligence activities onMyHealthDIRECT, PathCentral, Sonitus Medical and Wellfount Pharmacy. He is also a board observer at Delphinus Medical Technologies and MyHealthDIRECT.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Robert Cesaro invests in
Stages Robert Cesaro invests in
Countries Robert Cesaro invests in
Investment Focus
Industry
- Health Care 2 (33%)
- Medical Device 2 (33%)
- Information Technology 2 (33%)
- Medical 1 (17%)
- Software 1 (17%)
Stage
- Series B 2 (33%)
- Series D 2 (33%)
- Series A 1 (17%)
- Series C 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Delphinus Medical Technologies
|
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presenceof benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan. | $30.4M / Series D / Sep 13, 2022 | |
|
Delphinus Medical Technologies
|
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presenceof benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan. | $39.5M / Series C / Sep 10, 2015 | |
|
Delphinus Medical Technologies
|
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presenceof benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan. | $11M / Series B / Sep 03, 2013 | |
Sonitus Medical
|
Sonitus Medical Inc., is a privately held medical device company committed to providing innovative and clinically effective hearing solutions that Otologists, ENTs, and Audiologists can use to help their patients rejoin the conversation of life. As an emerging leader in bone conduction hearing devices, Sonitus Medical currently markets theSoundBite Hearing System, the world's first non-invasive and removable hearing solution that imperceptibly transmits sound via teeth. Relying on the principle of bone conduction, this nearly invisible ITM (in-the-mouth) hearing system is a simple and non-surgical solution that is currently FDA cleared as a prosthetic device for the treatment of single sided deafness and conductive hearing loss. Intended future applications for this platform technology include indications for hearing disorders such as mixed hearing loss and tinnitus, as well as consumer and covert communications. Founded in June 2006, Sonitus Medical is headquartered in San Mateo, California. | $25M / Series D / May 15, 2012 | |
PathCentral
|
PathCentral, an Irvine, California-based provider of a fully integrated, web-based enterprise software platform designed specifically for community pathologists. Created by a team of pathologists and industry executives, PathCentral's solution integrates all aspects of a pathology practice's business, including ordering (accessioning),barcode-based laboratory workflow management and specimen tracking, transcription, test send-outs, professional consultations, diagnosis, reporting, billing and financial analysis. | $10M / Series B / Nov 02, 2010 | |
|
Delphinus Medical Technologies
|
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presenceof benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan. | $8M / Series A / Jul 21, 2010 |
Co-Investors
Beringea
4 deals together
North Coast Technology Investors
4 deals together
Hopen Life Science Ventures
2 deals together
Venture Investors
2 deals together
Abingworth
1 deal together
About Arboretum Ventures
Arboretum Ventures is a Michigan-based venture capital firm. It specializes in seed-stage, early-stage, mid-stage investments, and growth capital. The company seeks to invest in healthcare sector with a focus on services, medical devices, diagnostics; healthcare information technology, therapeutics, technology based healthcare services, and lifescience tools. The firm invests throughout the United States with a focus on Midwest and Michigan. It seeks to invest in companies with equity investment between $5 million and $15 million.Arboretum Ventures Jan Garfinkle in 2002 and is headquartered in Michigan.
Arboretum Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Paul McCreadie
Managing Partner and Chief Operating Officer
|
|||
|
Robert Cesaro
Associate
|
|||
Tim Petersen
Founder and Managing Partner
|
|||
Amanda Goldstein
Executive Assistant
|
|||
George Dunbar
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Robert Cesaro invest in?
Robert Cesaro invests primarily in Health Care, Medical Device and Information Technology startups, most often at Series B and Series D stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Robert Cesaro last invest?
The most recent investment recorded for Robert Cesaro closed in Sep 2022. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
